Phase II study of paclitaxel given once per week along with trastuzumab and pertuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer

Journal of Clinical Oncology

Volumn 33, Issue 5, 2015, Pages 442-447

  Dang, Chau ^a   Iyengar, Neil ^a   Datko, Farrah ^a   D'Andrea, Gabriella ^a   Theodoulou, Maria ^a   Dickler, Maura ^a   Goldfarb, Shari ^a   Lake, Diana ^a   Fasano, Julie ^a   Fornier, Monica ^a   Gilewski, Theresa ^a   Modi, Shanu ^a   Gajria, Devika ^a   Moynahan, Mary Ellen ^a   Hamilton, Nicola ^a   Patil, Sujata ^a   Jochelson, Maxine ^a   Norton, Larry ^a   Baselga, Jose ^a   Hudis, Clifford ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CARVEDILOL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FUROSEMIDE; LISINOPRIL; PACLITAXEL; PERTUZUMAB; TRASTUZUMAB; ANTINEOPLASTIC AGENT; ERBB2 PROTEIN, HUMAN; MONOCLONAL ANTIBODY; TUMOR MARKER;

ACNE; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALOPECIA; ANOREXIA; ARTHRALGIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BREAST METASTASIS; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CONTROLLED STUDY; COUGHING; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG TOLERABILITY; DRY SKIN; DYSPEPSIA; DYSPNEA; EPISTAXIS; FATIGUE; FEMALE; FOLLOW UP; HAND FOOT SYNDROME; HEART FAILURE; HOT FLUSH; HUMAN; KAPLAN MEIER METHOD; LEFT VENTRICULAR SYSTOLIC DYSFUNCTION; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MIDDLE AGED; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PERIPHERAL EDEMA; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SENSORY NEUROPATHY; SIDE EFFECT; TREATMENT DURATION; XEROPHTHALMIA; BREAST NEOPLASMS; CHEMISTRY; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG ADMINISTRATION; FLUORESCENCE IN SITU HYBRIDIZATION; IMMUNOHISTOCHEMISTRY; INTRAVENOUS DRUG ADMINISTRATION; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; INFUSIONS, INTRAVENOUS; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; PACLITAXEL; RECEPTOR, ERBB-2; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84922384344     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.57.1745     Document Type: Article

References (29)

1. Hudis CA: Trastuzumab: Mechanism of action and use in clinical practice. N Engl J Med 357:39-51, 2007
2. Slamon DJ, Clark GM, Wong SG, et al: Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177-182, 1987
3. Agus DB, Akita RW, Fox WD, et al: Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell 2:127-137, 2002
4. Slamon DJ, Leyland-Jones B, Shak S, et al: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783-792, 2001
5. Marty M, Cognetti F, Maraninchi D, et al: Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: The M77001 study group. J Clin Oncol 23:4265-4274, 2005
6. Jelovac D, Emens LA: HER2-directed therapy for metastatic breast cancer. Oncology 27:166-175, 2013
7. Romond E, Suman VJ, Jeong J-H, et al: Trastuzumab plus adjuvant chemotherapy for HER2-positive breast cancer: Final planned joint analysis of overall survival (OS) from NSABP B-31 and NCCTG N9831. Presented at the 35th Annual CTRC-AACR San Antonio Breast Cancer Symposium, San Antonio, TX, December 4-8, 2012 (abstr S5-5)
8. Goldhirsch A, Piccart-Gebhart MJ, Procter M, et al: HERA Trial: 2 years versus 1 year of trastuzumab after adjuvant chemotherapy in women with HER2-positive early breast cancer at 8 years of median follow up. Presented at the 35th Annual CTRC-AACR San Antonio Breast Cancer Symposium, San Antonio, TX, December 4-8, 2012 (abstr S5-2)
9. Slamon DJ, Eiermann W, Robert N, et al: Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 365:1273-1283, 2011
10. Joensuu H, Kellokumpu-Lehtinen PL, Bono P, et al: Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 354:809-820, 2006
11. Spielmann M, Roche H, Humblet Y, et al: 3 year follow-up of trastuzumab following adjuvant chemotherapy in node positive HER2-positive breast cancer patients: Results of the PACS-04 trial. Breast Cancer Res Treat 106:S72, 2007
12. Perez EA, Suman VJ, Davidson NE, et al: Sequential versus concurrent trastuzumab in adjuvant chemotherapy for breast cancer. J Clin Oncol 29:4491-4497, 2011
13. Pivot X, Romieu G, Bonnefoi H, et al: PHARE trial results of subset analysis comparing 6 to 12 months of trastuzumab in adjuvant early breast cancer. Presented at the 35th Annual CTRC-AACR San Antonio Breast Cancer Symposium, San Antonio, TX, December 4-8, 2012 (abstr S5-3)
14. Dang C, Fornier M, Sugarman S, et al: The safety of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel with trastuzumab in HER-2/neu overexpressed/amplified breast cancer. J Clin Oncol 26:1216-1222, 2008
15. Franklin MC, Carey KD, Vajdos FF, et al: Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. Cancer Cell 5:317-328, 2004
16. Baselga J, Cortés J, Kim SB, et al: Pertuzumab plus trastuzumab plus docetaxel for meta-static breast cancer. N Engl J Med 366:109-119, 2012
17. Swain SM, Kim S-B, Corés J, et al: Final overall survival (OS) analysis from the CLEOPATRA study of first-line (1L) pertuzumab (Ptz), trastuzumab (T), and docetaxel (D) in patients with HER2-positive metastatic breast cancer (MBC). Presented orally at the European Society of Medical Oncology, Madrid, Spain, September 26-30, 2014
18. US Food and Drug Administration: Drug Approvals and Databases: Pertuzumab. www.fda.gov/drugs/informationondrugs/./ucm307592.htm
19. Eniu A, Palmieri FM, Perez EA: Weekly administration of docetaxel and paclitaxel in metastatic or advanced breast cancer. Oncologist 10:665-685, 2005
20. De Laurentiis M, Cancello G, D'Agostino D, et al: Taxane-based combinations as adjuvant chemotherapy of early breast cancer: A meta-analysis of randomized trials. J Clin Oncol 26:44-53, 2008
21. Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Peto R, Davies C, et al: Comparisons between different polychemotherapy regimens for early breast cancer: Meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet 379:432-444, 2012
22. Sparano JA, Wang M, Martino S, et al: Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med 358:1663-1671, 2008
23. Perez EA, López-Vega JM, Del Mastro L, et al: Safety of pertuzumab plus trastuzumab plus vinorelbine for first-line treatment of patients with HER2-positive locally advanced or metastatic breast cancer. Presented at the 36th Annual CTRC-AACR San Antonio Breast Cancer Symposium, San Antonio, TX, December 10-14, 2013 (abstr P2-16-10)
24. ClinicalTrials.gov: A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer. http://clinicaltrials.gov/show/NCT01358877
25. ClinicalTrials.gov: A Study of Kadcyla (Trastuzumab Emtansine) Plus Perjeta (Pertuzumab) Following Anthracyclines in Comparison With Herceptin (Trastuzumab) Plus Perjeta and a Taxane Following Anthracy-clines as Adjuvant Therapy in Patients With Operable HER2-Positive Primary Breast Cancer. http://clinicaltrials-.gov/ct2/show/NCT01966471
26. National Cancer Institute: FDA Approval for Pertuzumab: Brand name-Perjeta. http://www.cancer.gov/cancertopics/druginfo/fda-pertuzumab
27. Gianni L, Pienkowski T, Im YH, et al: Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): A randomised multicentre, open-label, phase 2 trial. Lancet Oncol 13: 25-32, 2012
28. Schneeweiss A, Chia S, Hickish T, et al: Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: A randomized phase II cardiac safety study (TRYPHAENA). Ann Oncol 24:2278-2284, 2013
29. National Cancer Institute: FDA Approval for Ado-Trastuzumab Emtansine: Brand name(s)-Kadcyla. http://www.cancer.gov/cancertopics/druginfo/fda-ado-trastuzumab-emtansine